14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
RGNX vs RARE: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Ultragenyx Pharmaceutical Inc. (RARE) is the stronger overall head-to-head candidate over REGENXBIO Inc. (RGNX) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). RGNX carries a Unified Composite Score of 45.3/100 (HOLD) at $7.47 (N/M Forward P/E, -120.4% operating margin), whereas RARE carries 43.8/100 (HOLD) at $15.96 (11.2x Forward P/E, -59.9% operating margin).
Composite vs. Pillar Nuance: While RGNX currently prints a higher short-term Unified Composite Score (45.3/100 HOLD vs. RARE 43.8/100 HOLD), RARE captures the overall institutional head-to-head verdict (6–3 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (-59.9% vs. -120.4% operating margin) and revenue trajectory (+8.1% vs. -69.2% YoY).
Technical & Structure Timing Caution: RGNX is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.3); meanwhile RARE is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Biotechnology value chain with $1.7B market capitalization and -59.9% operating margin.
OpEx & R&D Reinvestment49.2% of Rev ($359M)
90D Engineering Disclosures0 Published
Investor FAQ RGNX vs RARE Key Questions & Quantitative Answers
As of Nov 16, 2026, Ultragenyx Pharmaceutical Inc. (RARE) is the stronger overall head-to-head candidate over REGENXBIO Inc. (RGNX) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). RGNX carries a Unified Composite Score of 45.3/100 (HOLD) at $7.47 (N/M Forward P/E, -120.4% operating margin), whereas RARE carries 43.8/100 (HOLD) at $15.96 (11.2x Forward P/E, -59.9% operating margin). Composite vs. Pillar Nuance: While RGNX currently prints a higher short-term Unified Composite Score (45.3/100 HOLD vs. RARE 43.8/100 HOLD), RARE captures the overall institutional head-to-head verdict (6–3 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (-59.9% vs. -120.4% operating margin) and revenue trajectory (+8.1% vs. -69.2% YoY). Technical & Structure Timing Caution: RGNX is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.3); meanwhile RARE is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
RARE leads the Growth & Scale pillar: RGNX posts -69.2% YoY revenue growth and +0.0% YoY earnings growth on $154M TTM revenue (-64.5% gross margin, -120.4% operating margin), compared with RARE at +8.1% YoY revenue growth and +0.0% YoY earnings growth on $730M TTM revenue (-10.7% gross margin, -59.9% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), RGNX cumulative revenue shifted -22.7% while RARE shifted +1240.0%. In operating R&D and SG&A reinvestment, RGNX deploys 55.9% of Rev ($86M) (0 90-day corporate R&D disclosures) versus 49.2% of Rev ($359M) (0 disclosures) for RARE.
RARE screens cheaper on headline valuation multiples. RGNX trades at N/M Forward P/E, N/M Trailing P/E, 0.26x PEG, and 3.1x EV/Revenue (-100.6% FCF margin), whereas RARE trades at 11.2x Forward P/E, N/M Trailing P/E, N/M PEG, and 2.3x EV/Revenue (-61.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RGNX (-113.2% ROE) versus RARE (-608.5% ROE) capital efficiency.
In options market volatility and institutional positioning, RGNX carries 349.6% implied volatility (52nd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.81β · 76% Vol realized risk). By comparison, RARE carries 171.9% implied volatility (38th %ile, Balanced (25th–60th %ile)), a 0.40x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.41β · 58% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.